These strategies not only inhibit angiogenesis but also enhance the efficacy of chemotherapy and immunotherapy by remodeling the TME.[79, 80] Our study demonstrates that targeting the ENH/CCL5 axis shows strong antiangiogenic and anti‐tumor activity by suppressing TAMs recruitment and M2 polarization, along with significantly improving chemotherapy outcomes. The gene discussed is PDLIM5; the disease is neoplasm.